{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Obr A"],"funding":["Internal grant agency","Ministry of Health of the Czech Republic","The Leukemia & Lymphoma Society (LLS)","Czech Science Foundation","the European Union - Next Generation EU"],"pagination":["306"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12481964"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(1)"],"pubmed_abstract":["Background
Previous studies have suggested that, after acquisition of t(11;14), mantle cell lymphoma (MCL) pathogenesis may proceed via several different genetic second hits, which may shape different mutational profiles of clinically manifest lymphoma. The most prevalent second hit in MCL includes ATM aberrations, accounting for about half of patients with newly diagnosed MCL. As ATM and TP53 mutations tend to be exclusive in MCL, we retrospectively analyzed the prognostic role of ATM deletions and/or mutations in patients with newly diagnosed MCL, both in the entire cohort and in a subcohort of patients with wild-type TP53.Methods
To investigate deletions and mutations of ATM and TP53 in newly diagnosed MCL, we used fluorescence in situ hybridization and next-generation s"],"journal":["Molecular medicine (Cambridge, Mass.)"],"pubmed_title":["Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma."],"pmcid":["PMC12481964"],"funding_grant_id":["MCL 7005-24","IGA_LF_2025_005","JG_2024_035","GA23-05377S","MH CZ-DRO-VFN-64165","EXCELES, ID Project No. LX22NPO5102","MH CZ - DRO (FNOl, 00098892)"],"pubmed_authors":["Vatolikova M","Papajik T","Petrackova A","Forsterova K","Obr A","Manakova J","Trneny M","Malarikova D","Flodr P","Hanackova V","Furst T","Zemanova Z","Prochazka V","Berkova A","Urbankova H","Klener P","Hruskova A","Kriegova E"],"additional_accession":[]},"is_claimable":false,"name":"Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma.","description":"Background
Previous studies have suggested that, after acquisition of t(11;14), mantle cell lymphoma (MCL) pathogenesis may proceed via several different genetic second hits, which may shape different mutational profiles of clinically manifest lymphoma. The most prevalent second hit in MCL includes ATM aberrations, accounting for about half of patients with newly diagnosed MCL. As ATM and TP53 mutations tend to be exclusive in MCL, we retrospectively analyzed the prognostic role of ATM deletions and/or mutations in patients with newly diagnosed MCL, both in the entire cohort and in a subcohort of patients with wild-type TP53.Methods
To investigate deletions and mutations of ATM and TP53 in newly diagnosed MCL, we used fluorescence in situ hybridization and next-generation s","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-04T01:37:37.433Z","creation":"2026-05-04T03:12:02.339Z"},"accession":"S-EPMC12481964","cross_references":{"pubmed":["41023839"],"doi":["10.1186/s10020-025-01376-2"]}}